LLY.SW stock down 5.99% pre-market to CHF 785.00: key targets and outlook

LLY.SW stock drops -5.99% in pre-market trading to CHF 785.00, a CHF 50.00 fall from yesterday’s close of CHF 835.00. The move places Eli Lilly and Company (LLY.SW) among top pre-market losers on the SIX exchange in Switzerland and follows a sharp intraday repricing versus the 50-day average of CHF 840.90. Traders should note volume is currently 0.00 (average 14.00), so the price move reflects pre-market quotes ahead of the company’s next earnings announcement on 2026-02-04. We summarise valuation, technicals, Meyka forecasts and near-term price targets to guide Swiss-market investors.

LLY.SW stock: pre-market price action and drivers

Eli Lilly (LLY.SW) is quoted at CHF 785.00 pre-market, down CHF 50.00 or -5.99% from the previous close of CHF 835.00. The day’s open equals the last trade at CHF 785.00 and reported volume is 0.00 as markets prepare for U.S. earnings and macro updates. Year range sits at CHF 540.00 to CHF 880.00, so the stock is trading nearer to the high than the low, increasing sensitivity to catalysts.

LLY.SW stock: valuation and fundamentals snapshot

LLY.SW trades at a trailing PE of 50.06 with EPS of CHF 15.58, implying premium growth expectations. Market capitalisation is approximately CHF 600.99B. Key per-share metrics include Revenue/Share CHF 66.25, Free Cash Flow/Share CHF 10.06, and Book Value/Share CHF 26.59. Debt to equity is 1.79, and the dividend yield is a modest 0.62%, underlining Lilly’s capital allocation toward R&D and growth.

LLY.SW stock: Meyka AI grade and model forecast

Meyka AI rates LLY.SW with a score out of 100: 72.67/100 — Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target CHF 926.03 (+17.96% vs CHF 785.00) and a yearly target CHF 988.71 (+25.97%). A nearer-term quarterly model shows CHF 744.60 (-5.15%). Forecasts are model-based projections and not guarantees.

LLY.SW stock: technical indicators and trend read

Momentum indicators show mixed signals: RSI 55.14 and MACD histogram negative at -5.36, suggesting short-term pullback inside a broader uptrend (50-day average CHF 840.90, 200-day CHF 687.43). Bollinger Bands middle is CHF 839.25 with lower band CHF 791.06, so the pre-market price is near the lower envelope and could test support around CHF 785.00. ADX 27.07 indicates a strengthening trend.

LLY.SW stock: catalysts, earnings and risk factors

Key near-term catalyst is the earnings announcement on 2026-02-04 which may drive volatility. Clinical trial updates, diabetes and obesity drug sales trends, and pricing developments are principal news drivers. Risks include high valuation (PE 50.06) and elongated inventory metrics; days-of-inventory is elevated, which could pressure margins if demand weakens. Regulatory or competitive setbacks would likely deepen the current sell-off.

LLY.SW stock: how sector context shapes the move

Healthcare peers in Switzerland show a 3-month average performance of 12.25%, and the sector PE average is 34.54, placing Eli Lilly’s valuation premium in context. Sector strength supports recovery potential, but the stock’s price-to-sales of 13.21 and price/book 38.41 elevate sensitivity to growth execution. For further company-specific data visit our Meyka page for LLY.SW analysis Meyka LLY.SW page.

Final Thoughts

LLY.SW stock’s pre-market drop to CHF 785.00 (-5.99%) reflects short-term repricing ahead of earnings and highlights valuation sensitivity. Our Meyka AI grade of 72.67/100 (B+, BUY) balances strong recent growth, robust cash flow (Free Cash Flow/Share CHF 10.06), and a premium PE 50.06. Meyka AI’s forecast model shows a mixed near-term picture: a quarterly target CHF 744.60 (-5.15%) that suggests possible short-term downside, versus a monthly target CHF 926.03 (+17.96%) and a yearly target CHF 988.71 (+25.97%) that imply significant upside if growth holds. Investors should watch the 2026-02-04 earnings release and clinical updates; high valuation and inventory metrics are the main risks. Our analysis is data-driven and not investment advice—forecasts are model-based projections and not guarantees. For dividend history and related company filings see Nasdaq and sector ETF context at MarketWatch source source. Meyka AI is the AI-powered market analysis platform used to generate the grade and forecasts above.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.